MX2020004403A - Composiciones farmaceuticas que comprenden safinamida. - Google Patents

Composiciones farmaceuticas que comprenden safinamida.

Info

Publication number
MX2020004403A
MX2020004403A MX2020004403A MX2020004403A MX2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A MX 2020004403 A MX2020004403 A MX 2020004403A
Authority
MX
Mexico
Prior art keywords
safinamide
pharmaceutical compositions
particles
taste
prepare
Prior art date
Application number
MX2020004403A
Other languages
English (en)
Inventor
Lazzari Alessandra De
Alberto Moretto
Fabiana Mazzara
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of MX2020004403A publication Critical patent/MX2020004403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas que comprenden la safinamida y, más particularmente, con partículas que enmascaran el sabor, que comprenden el ingrediente activo tal o las sales farmacéuticamente aceptables del mismo, formas de dosificación oral que incluyen las partículas tales y un proceso para prepararlas.
MX2020004403A 2017-11-02 2018-10-30 Composiciones farmaceuticas que comprenden safinamida. MX2020004403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201700124545 2017-11-02
PCT/EP2018/079635 WO2019086408A1 (en) 2017-11-02 2018-10-30 Pharmaceutical compositions comprising safinamide

Publications (1)

Publication Number Publication Date
MX2020004403A true MX2020004403A (es) 2020-08-06

Family

ID=61527030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004403A MX2020004403A (es) 2017-11-02 2018-10-30 Composiciones farmaceuticas que comprenden safinamida.

Country Status (13)

Country Link
US (1) US11103457B2 (es)
EP (1) EP3703665A1 (es)
JP (1) JP2021508316A (es)
CN (1) CN111432806A (es)
AU (1) AU2018357886B2 (es)
BR (1) BR112020008653A2 (es)
CA (1) CA3080975A1 (es)
CO (1) CO2020006552A2 (es)
EA (1) EA202091127A1 (es)
IL (1) IL274144A (es)
MX (1) MX2020004403A (es)
WO (1) WO2019086408A1 (es)
ZA (1) ZA202003079B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096791A1 (en) * 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
JP5680898B2 (ja) * 2010-08-10 2015-03-04 京都薬品工業株式会社 苦味を抑制した速崩壊錠
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
EP2594266B1 (en) 2011-11-17 2014-07-30 Zambon S.p.A. Pharmaceutical solid compositions containing ibuprofen salts
CA2900597C (en) * 2013-02-14 2021-11-02 Sanofi Chewable composition for oral administration and process for preparing thereof
AU2014228861B2 (en) * 2013-03-15 2018-05-24 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of topiramate
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
CA2955972A1 (en) * 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN104546747A (zh) 2014-11-20 2015-04-29 美吉斯制药（厦门）有限公司 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
ITUA20163981A1 (it) * 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
CN106667940A (zh) 2017-02-22 2017-05-17 佛山市弘泰药物研发有限公司 一种沙芬酰胺分散片及其制备方法
CN106983730A (zh) * 2017-02-22 2017-07-28 佛山市弘泰药物研发有限公司 一种沙芬酰胺胃溶型微丸片及其制备方法

Also Published As

Publication number Publication date
CN111432806A (zh) 2020-07-17
AU2018357886A1 (en) 2020-05-07
CO2020006552A2 (es) 2020-08-21
CA3080975A1 (en) 2019-05-09
ZA202003079B (en) 2023-02-22
BR112020008653A2 (pt) 2020-10-27
WO2019086408A1 (en) 2019-05-09
AU2018357886B2 (en) 2024-04-18
US11103457B2 (en) 2021-08-31
IL274144A (en) 2020-06-30
EP3703665A1 (en) 2020-09-09
JP2021508316A (ja) 2021-03-04
EA202091127A1 (ru) 2020-09-22
US20200315969A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2020000747A1 (es) Formulaciones de niraparib.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
BR112017004948A2 (pt) formulação farmacêutica.
MX2020012989A (es) Agente terapeutico para la fibrosis.
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CL2017002229A1 (es) Inhibidores de bace1.
BR112019001024A2 (pt) combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas
MX2020004403A (es) Composiciones farmaceuticas que comprenden safinamida.
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12016502527B1 (en) Stabilized desmopressin